Cargando…

Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience

PURPOSE: This study evaluates whether race, socioeconomic status, insurance type, oncological provider type, and prior cancer treatment are associated with the suggestion and acceptance of hormonal therapy in patients with estrogen receptor (ER)-positive Ductal carcinoma in situ (DCIS). This study a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levy, Julia, Farag, Fady, Cole, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550728/ https://www.ncbi.nlm.nih.gov/pubmed/36083381 http://dx.doi.org/10.1007/s10549-022-06735-9

Ejemplares similares

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands
por: Luiten, Jacky D., et al.
Publicado: (2021)

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors
por: Truin, Wilfred, et al.
Publicado: (2017)

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ
por: Anderson, Chelsea, et al.
Publicado: (2017)

Ductal carcinoma in situ of the breast, a population-based study of epidemiology and pathology
por: Kricker, A, et al.
Publicado: (2004)

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
por: Makubate, B, et al.
Publicado: (2013)

Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity
por: Wulaningsih, W., et al.
Publicado: (2018)

Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study
por: Doebar, Shusma C., et al.
Publicado: (2016)

Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center
por: Nicosia, Luca, et al.
Publicado: (2022)

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study
por: Mannu, Gurdeep S., et al.
Publicado: (2019)

Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands
por: van Dooijeweert, Carmen, et al.
Publicado: (2018)

Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study
por: Rohan, Thomas E, et al.
Publicado: (2021)

Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
por: Chen, Yunn-Yi, et al.
Publicado: (2009)

Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study
por: Schiza, Aglaia, et al.
Publicado: (2020)

Investigating the effectiveness of adjuvant therapy for patients with hormone receptor-positive ductal carcinoma in situ
por: Tsai, Chi-Jui, et al.
Publicado: (2022)

Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women
por: Bertrand, Kimberly A., et al.
Publicado: (2019)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women
por: Elshof, Lotte E., et al.
Publicado: (2016)

Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer
por: Land, L H, et al.
Publicado: (2012)

Tamoxifen Initiation After Ductal Carcinoma In Situ
por: Nichols, Hazel B., et al.
Publicado: (2016)

Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study
por: Xie, Yuxin, et al.
Publicado: (2022)

Treatment results in patients with ductal carcinoma in situ treated with adjuvant radiotherapy
por: GÜZELÖZ, Zeliha, et al.
Publicado: (2019)

Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic
por: Williams, Austin D., et al.
Publicado: (2021)

ENDOCRINE DISRUPTORS: Estrogens in a Bottle?
por: Barrett, Julia R.
Publicado: (2009)

Breast Ductal Carcinoma In Situ: A Literature Review of Adjuvant Hormonal Therapy
por: Kinsey-Trotman, Stephen, et al.
Publicado: (2016)

Estrogen receptor α polymorphisms and postmenopausal breast cancer risk
por: González-Zuloeta Ladd, A. M., et al.
Publicado: (2007)

Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma
por: Sugiura, Teiichi, et al.
Publicado: (2020)

Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort
por: Persson, Mia, et al.
Publicado: (2016)

Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast
por: Chen, A C, et al.
Publicado: (2014)

Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival
por: Morales-Oyarvide, Vicente, et al.
Publicado: (2017)

Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers
por: Lobbes, Marc B.I., et al.
Publicado: (2017)

The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer
por: Kleeff, Jörg, et al.
Publicado: (2016)

Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study
por: Niu, Nan, et al.
Publicado: (2023)

Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study
por: Costas, L, et al.
Publicado: (2015)

The Selection of Treatment Modality for Breast Ductal Carcinoma In Situ: Experience From a Single Institution
por: You, Kai-yun, et al.
Publicado: (2021)

Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk
por: Sund, Maria, et al.
Publicado: (2023)

Influence of Endogenous and Exogenous Estrogenic Endocrine on Intestinal Microbiota in Zebrafish
por: Liu, Yukun, et al.
Publicado: (2016)

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
por: Park, Ko Un, et al.
Publicado: (2021)

Familial invasive and in situ squamous cell carcinoma of the skin
por: Hemminki, K, et al.
Publicado: (2003)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ga13to5eg4ht087c9p3unjgsqg